Clinical Trial

Evaluate the Safety and Clinical Activity of HH2853

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-05-14; most recent amendment 2026-01-28.
Status change: Not Yet Recruiting → Recruiting 2020-08-25
Trial Details
NCT Number NCT04390737
Lead Sponsor Haihe Biopharma Co., Ltd.
Conditions FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
Enrollment 254 participants
Start Date 2020-09-08
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-30